TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development.

The presentations from the 4th International Workshop on Clin. Pharm. of TB Drugs are available [click here].

Key abstracts from ICAAC were:

Authors Abstract Title
  • Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg

Pyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
  • A. Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg
Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB
  • R. Tasneen, S. Li, K. Andries, K. Mdluli, E. Nuermberger
Novel TMC207-containing Regimens Have Sterilizing Activity In Murine Tuberculosis
  • H. Huang , K. Liu, D. Zhang, B. Liu, G. Zhang, H. Zhang, Y. Li, Master C. Zhang, Y. Liu, J. Wang, Y. Lu, M. Zheng, B. Wang, T. Yang, X. Li, C. Li, C. B. Cooper, Z. Ma, D. Yin
SAR of Riminophenazine Class and Discovery of New Anti-tuberculosis Agents Active Against Multidrug-Resistant Tuberculosis
  • Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, D. Yin, H. Huang, Z. Ma

Clofazimine Analogs with Superior Efficacy against Experimental Tuberculosis and Reduced Potential

for Tissue Discoloration

  • M. Upton, A. Shadiack, Z. Ma, Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu,
  • H. Jin, D. Yin, H. Huang
Anti-tubercular Clofazimine Analogs that Demonstrate a Range of Tissue Distribution Patterns Following Eight Weeks Dosing to Mice
  • K. C. Chang, W. W. Yew, S. W. Cheung, C. C. Leung
Extensively Drug-resistant Tuberculosis (XDR-TB) Treated with Daily/ Intermittent Linezolid
  • L. Manzini, M. Parracino, D. Iemmi, G. Lapadula, A. Gori, E. Girardi, C. Mussini
Tolerability of Moxifloxacin as Part of Anti-Tuberculous Treatment

Additional TB R&D News:

Epistem successfully completes first-round testing of TB diagnostic device

Lilly Launches Open Innovation Drug Discovery Platform to Help Find Potential New Medicines Where Medical Need is Great

Open Innovation Drug Discovery [Actual Website]

Drug-Evading Tuberculosis Shows Rising Superbug Threat in China

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...